PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma

Abstract Despite increasing incidence, treatment for hepatoblastoma has not changed significantly over the past 20 years. Chemotherapeutic strategies continue to rely on cisplatin, as it remains the most active single agent against hepatoblastoma. However, chemoresistance remains a significant chall...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Raoud Marayati, Laura L. Stafman, Adele P. Williams, Laura V. Bownes, Colin H. Quinn, Jamie M. Aye, Jerry E. Stewart, Karina J. Yoon, Joshua C. Anderson, Christopher D. Willey, Elizabeth A. Beierle
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/651d99d3286c48f987b6b07498bbc8c8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!